BRPI0512593A - compound or a pharmaceutically acceptable salt or prodrug or solvate thereof, composition, and methods of inhibiting checkpoint kinase 1 in a cell, sensitizing cells in an individual and inhibiting aberrant cell proliferation - Google Patents

compound or a pharmaceutically acceptable salt or prodrug or solvate thereof, composition, and methods of inhibiting checkpoint kinase 1 in a cell, sensitizing cells in an individual and inhibiting aberrant cell proliferation

Info

Publication number
BRPI0512593A
BRPI0512593A BRPI0512593-6A BRPI0512593A BRPI0512593A BR PI0512593 A BRPI0512593 A BR PI0512593A BR PI0512593 A BRPI0512593 A BR PI0512593A BR PI0512593 A BRPI0512593 A BR PI0512593A
Authority
BR
Brazil
Prior art keywords
inhibiting
methods
solvate
compound
pharmaceutically acceptable
Prior art date
Application number
BRPI0512593-6A
Other languages
Portuguese (pt)
Inventor
Laurence Edward Burgess
Adam Wade Cook
Kimba L Fischer
Stephen T Schlachter
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of BRPI0512593A publication Critical patent/BRPI0512593A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

COMPOSTO OU UM SAL OU PRó-DROGA OU SOLVATO FARMACEUTICAMENTE ACEITáVEL DO MESMO, COMPOSIçãO, E, MéTODOS DE INIBIR A QUINASE 1 DE PONTO DE VERIFICAçãO EM UMA CéLULA, DE SENSIBILIZAR CéLULAS EM UM INDIVìDUO E DE INIBIR A PROLIFERAçãO DE CéLULA ABERRANTE Compostos de uréia substituídos por afila e heteroarila úteis no tratamento de doenças e condições relacionadas ao dano ao DNA ou lesões na replicação do DNA são divulgados. Os métodos de fabricar os compostos, e seu uso como agentes terapêuticos, por exemplo, no tratamento do câncer e outras doenças caracterizadas por deficiências na replicação do DNA, segregação cromossómica, ou divisão celular também são divulgados.Fórmula (I)COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OR PRODUCT OR SOLVATE OF THE SAME COMPOSITION, AND METHODS OF INHIBITING A CHECK POINT KINASE 1, SENSITIZING CELLS IN A CIRCULAR INDIVIDUAL AULA, AND Alkyl and heteroaryl substituted compounds useful in the treatment of diseases and conditions related to DNA damage or damage to DNA replication are disclosed. Methods of manufacturing the compounds, and their use as therapeutic agents, for example in the treatment of cancer and other diseases characterized by deficiencies in DNA replication, chromosomal segregation, or cell division are also disclosed. Formula (I)

BRPI0512593-6A 2004-06-25 2005-06-24 compound or a pharmaceutically acceptable salt or prodrug or solvate thereof, composition, and methods of inhibiting checkpoint kinase 1 in a cell, sensitizing cells in an individual and inhibiting aberrant cell proliferation BRPI0512593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58308004P 2004-06-25 2004-06-25
PCT/US2005/022515 WO2006012308A1 (en) 2004-06-25 2005-06-24 Bisarylurea derivatives useful for inhibiting chk1

Publications (1)

Publication Number Publication Date
BRPI0512593A true BRPI0512593A (en) 2008-03-25

Family

ID=35307890

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512593-6A BRPI0512593A (en) 2004-06-25 2005-06-24 compound or a pharmaceutically acceptable salt or prodrug or solvate thereof, composition, and methods of inhibiting checkpoint kinase 1 in a cell, sensitizing cells in an individual and inhibiting aberrant cell proliferation

Country Status (9)

Country Link
EP (1) EP1765808A1 (en)
JP (1) JP2008504283A (en)
KR (1) KR20070028591A (en)
CN (1) CN101006075A (en)
AU (1) AU2005267185A1 (en)
BR (1) BRPI0512593A (en)
CA (1) CA2571424A1 (en)
MX (1) MX2007000259A (en)
WO (1) WO2006012308A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778648A2 (en) * 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
ES2356068T3 (en) 2005-03-29 2011-04-04 Icos Corporation DERIVATIVES OF HETEROARIL UREA USEFUL TO INHIBIT CHK1.
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (en) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 Chk1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas
WO2023287839A2 (en) * 2021-07-13 2023-01-19 Brown University Urinary tract cancer treatment guided by mutational landscape
CA3233080A1 (en) * 2021-09-28 2023-04-06 Pioneer Hi-Bred International, Inc. Seedling germination and growth conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163723A (en) * 1987-12-21 1989-06-28 Nippon Telegr & Teleph Corp <Ntt> Organic nonlinear optical material
JPH09249628A (en) * 1996-03-12 1997-09-22 Tanabe Seiyaku Co Ltd Derivatives of phenol
ATE297383T1 (en) * 1997-12-22 2005-06-15 Bayer Pharmaceuticals Corp INHIBITION OF P38 KINASE USING SYMMETRIC AND ASYMMETRIC DIPHENYL UREASES
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
JP2005503400A (en) * 2001-09-13 2005-02-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Method for treating cytokine-mediated diseases
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors

Also Published As

Publication number Publication date
CA2571424A1 (en) 2006-02-02
MX2007000259A (en) 2007-07-20
AU2005267185A1 (en) 2006-02-02
KR20070028591A (en) 2007-03-12
EP1765808A1 (en) 2007-03-28
WO2006012308A1 (en) 2006-02-02
CN101006075A (en) 2007-07-25
JP2008504283A (en) 2008-02-14

Similar Documents

Publication Publication Date Title
BRPI0514466A (en) compound, composition, and methods of inhibiting control point kinase 1 in a cell, sensitizing cells, and inhibiting aberrant cell proliferation
BRPI0512891A (en) compound and a pharmaceutically acceptable salt or prodrug or solvate thereof, composition, methods of inhibiting checkpoint kinase 1 in a cell, of sensitizing cells in an individual undergoing chemotherapeutic or radiotherapeutic treatment for a medical condition and of inhibiting aberrant cell proliferation, use of a compound, and article of manufacture for pharmaceutical use in human
NO20074391L (en) CIS-2,4,5-triaryl imidazolines and their use as anti-cancer drugs
BR112012032234A2 (en) &#34;heteroaryl imidazolone derivatives as jak inhibitors&#34;.
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
BRPI0108841B8 (en) pyrimidine derivative, process for preparing the same, and pharmaceutical composition
BRPI0511512A (en) pyrrolpyrimidine derivatives useful in cancer treatment
NO20090443L (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives
BRPI0821115A8 (en) AMINOTRIAZOLE DERIVATIVE COMPOUND, DRUG, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND
AR047531A1 (en) DERIVATIVES 1H-TIENO (2,3-C) PIRAZOL USEFUL AS QUINASE INHIBITORS
NO20055496L (en) Pyrazoloquinazoline derivatives, methods for their preparation and their use as kinase inhibitors
ATE557015T1 (en) 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS
BR0008770A (en) Pyrimidine derivative, process for the preparation of a pyrimidine derivative, process for producing an anti-cancer effect in a warm-blooded animal, use of a pyrimidine derivative, and pharmaceutical composition
ATE430743T1 (en) BENZIMIDAZOLE SUBSTITUTED THIOPHENE DERIVATIVES ACTING ON IKK3
BRPI0515499A (en) pyridine derivatives for inhibition of human stearoyl coa desaturase
BRPI0515500A (en) pyridazine derivatives for stearoyl coa desaturase inhibition
BRPI0514125A (en) condensed pyridines as kinase inhibitors
TW200740805A (en) Novel compounds
BRPI0716171A8 (en) COMPOUND, PHARMACEUTICAL COMPOSITION AND USE OF A COMPOUND
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
TN2010000167A1 (en) Organic compounds
EA200501332A1 (en) DERIVATIVES OF PYRIMIDIN-4-IT AND THEIR APPLICATION AS KINAZA P38 MODULATORS
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
ES2368594T3 (en) SUBSTITUTED DERIVATIVES OF CYCLOHEXILMETILO.
BR112012010124B8 (en) compound derived from chromenone or a pharmaceutically acceptable salt thereof that has antitumor activity

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.